Clinical HIV Guidelines
Clinical HIV Guidelines, 5th Edition, 2022. Ministry of Health and Population, Malawi.
1How to use these guidelines?
2Summary of key policies
3Implementation plan
4Integrating HIV clinical services
5eMTCT Strategy
6Diagnosing HIV infection and exposure
7WHO Clinical Staging
8HIV-related diseases
- 8HIV-related diseases
- 8.1Routine urine LAM and serum CrAg screening
- 8.2.1Cryptococcal Meningitis (CM)
- 8.2.2Cryptococcocaemia
- 8.2.3Toxoplasmosis
- 8.2.4Oral candidiasis
- 8.2.5Oesophageal candidiasis
- 8.2.6TB
- 8.2.7Pneumonia
- 8.2.8Pneumocystis jirovecii pneumonia (PJP)
- 8.2.9Sepsis
- 8.2.10Kaposi sarcoma
- 8.2.11Lymphoma
- 8.2.12Cervical (pre-) cancer
- 8.2.13Herpes zoster (shingles)
- 8.2.14Seborrhoeic dermatitis
- 8.2.15Tinea corporis / cruris / pedis
- 8.2.16Pruritic papular eruptions
- 8.2.17Chronic diarrhoea
- 8.2.18Sexually Transmitted Diseases
9HIV and COVID-19
10Standard monitoring of HIV patients
11Preventive services for HIV patients
12Management of non-communicable diseases
- 12Management of non-communicable diseases
- 12.1Lifestyle modification to prevent NCDs
- 12.2Detecting and managing high blood pressure
- 12.3Diabetes mellitus
- 12.4Mental health and psychosocial support
- 12.4.1Depression screening and management
- 12.4.2Substance use disorder in PLHIV
- 12.5Cervical cancer screening in WLHIV
13HIV and viral hepatitis
14Understanding ART regimens and formulations
- 14Understanding ART regimens and formulations
- 14.1Classification of individual ARVs
- 14.1.1Regimen names
- 14.1.2Paediatric / adult formulations
- 14.1.3Choosing ART regimen, formulation and dosage
- 14.1.4Initial prescriber level
- 14.1.5Contraindications
- 14.1.6Adverse events / side effects
- 14.1.7Dosing and frequency
- 14.2Choosing regimen and time of starting in special situations
- 14.3Non-standard (NS) ART regimens
15Prescribing and dispensing ARVs
16Starting ART
- 16Starting ART
- 16.1When to start ART
- 16.2Record keeping
- 16.3Confirming HIV infection
- 16.3.1Confirmatory testing for adults and children 2 years and above
- 16.3.2Confirmatory HIV testing for children under 2 years
- 16.4Preparing the patient for ART
- 16.4.1Mandatory patient education when starting ART
- 16.4.2Baseline and routine lab investigations
17Combining ART and TB treatment
18Continuing ART
- 18.1Confirming adherence to appointment
- 18.2Monitoring height and weight
- 18.3Monitoring for HIV-related diseases and drug side-effects
- 18.4Indications for interrupting or stopping ART
- 18.5Selecting regimen and formulation for continuation
- 18.6Routine TB screening (intensified case finding)
- 18.7Achieving optimal adherence
- 18.7.1Routine adherence support
- 18.7.2Intensive adherence counselling
- 18.8Welcoming patients back to care after treatment interruption
- 18.9Special treatment support for children and adolescents
- 18.9.1Managing the disclosure process
- 18.10.1Viral load (VL) testing
- 18.10.2Clinical screening and diagnosis of treatment failure
- 18.10.3Application for HIV drug resistance testing
- 18.11Updating follow-up outcome
- 18.12Immune reconstitution inflammatory syndrome (IRIS)
- 18.12.1Management of IRIS
19Differentiated ART services
20Management of labour and delivery
21Newborn care and postnatal follow up
22Pre-exposure prophylaxis (PrEP)
23Post exposure prophylaxis (PEP)
24Pharmacovigilance
25Monitoring and evaluation
26Supply Management
27HIV commodity supply cycle
28Appendix
Malawi Guidelines for Clinical Management of HIV in Children and Adults, 5th Edition (2022). Reproduced under the Ministry's standing permission for reproduction with acknowledgement.